Sanofi SA (EPA:SAN) received a €78.00 ($83.87) target price from equities research analysts at Jefferies Group in a research report issued to clients and investors on Friday. The brokerage currently has a a “neutral” rating on the stock.

Other research analysts have also issued research reports about the stock. Deutsche Bank AG set a €95.00 ($102.15) price objective on shares of Sanofi SA and gave the company a “buy” rating in a research note on Thursday, October 13th. BNP Paribas set a €78.00 ($83.87) price objective on shares of Sanofi SA and gave the company a “neutral” rating in a research note on Wednesday, September 14th. Societe Generale set a €100.00 ($107.53) price objective on shares of Sanofi SA and gave the company a “buy” rating in a research note on Monday, August 1st. JPMorgan Chase & Co. reiterated a “sell” rating on shares of Sanofi SA in a research note on Monday, October 31st. Finally, Morgan Stanley set a €77.00 ($82.80) price objective on shares of Sanofi SA and gave the company a “neutral” rating in a research note on Friday, November 4th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of €82.73 ($88.96).

Analyst Recommendations for Sanofi SA (EPA:SAN)

Sanofi SA (EPA:SAN) opened at 77.18 on Friday. The firm has a 50-day moving average of €25.66 and a 200-day moving average of €25.75. Sanofi SA has a one year low of €62.50 and a one year high of €84.81. The firm has a market cap of €99.33 billion and a price-to-earnings ratio of 23.68.

About Sanofi SA

Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.

Receive News & Stock Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related stocks with our FREE daily email newsletter.